Navigation Links
Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
Date:5/16/2011

ALLEGAN, Mich., May 16, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Ranitidine 150 (regular and cool mint), a generic version of Zantac 150®. We expect to launch early in our fiscal 2012.

Zantac 150 (ranitidine) is indicated for the relief of heartburn associated with acid indigestion and sour stomach and prevents heartburn associated with acid indigestion and sour stomach brought on by certain foods and beverages. It has annual sales of approximately $110 million, as measured by Information Resources, Inc.  

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This approval is the first from our Allegan, Michigan facility since the Company returned to acceptable regulatory status. It is another example of Perrigo's commitment to bring new products to market. Perrigo continues to deliver on its mission to provide quality, affordable healthcare to consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products.  The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).  

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Settlement of Cutivate Lotion Litigation
2. Perrigo to Introduce New Dosing System and Labeling for Certain Pediatric Pain Relievers
3. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
4. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
5. Perrigo Company Announces Quarterly Dividend
6. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
7. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
8. Perrigo Announces Conclusion of the FDA Re-Inspection
9. Perrigo Company to Present at the Barclays Capital 2011 Global Health Care Conference
10. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
11. Perrigo Company to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... OSWEGO, Ore. , Dec. 5, 2016   ... the BioInsight clinical study. The study evaluates the safety ... insertion procedure in an office setting. BioMonitor ... ® technology that is placed underneath a patient,s ... fibrillation and syncope (fainting). Atrial fibrillation is a leading ...
(Date:12/5/2016)... PITTSBURGH , Dec. 5, 2016  Wellbridge Health and ... innovative digital health solutions to Medicare and Medicaid plan members ... effort targeted at the unique needs of this group of ... on social work philosophies to provide insight into members, daily ... , ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known for myriad ... a show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a ... plummeted in large part due to early detection. Like any other disease, treatments have ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish ... take advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional ... appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity ...
(Date:12/4/2016)... ... ... Responsible dental care hinges on regular brushing of the teeth. However, just brushing ... inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. , ... bad techniques of brushing the teeth in order to prevent cavities," he said. "Children ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
Breaking Medicine News(10 mins):